What is Medtronic Hugo?

Medtronic Hugo: large-prime IDE-pivotal pathway archetype

Medtronic Hugo is the Hugo RAS (Robotic-Assisted Surgery) modular soft-tissue surgical system from Medtronic (NYSE: MDT). Per DEPLOY's surgical cluster framework, Hugo anchors the large-prime IDE-pivotal pathway archetype within the surgical cluster's FDA-clearance-posture axis. This Wave 3 backfill closes the Wave 1 surgical FDA-clearance triangle (Intuitive market-leader cleared + Hugo IDE-pivotal + Ottava De Novo pre-market) that was the framework's third leg missing from news anchors prior to this ship.

---

Medtronic: NYSE: MDT

Medtronic is one of the largest publicly-traded medical-device companies globally (NYSE: MDT) with substantial cardiac + diabetes + surgical + neuro + spine product portfolios. Hugo operates as Medtronic's robotic-assisted surgery vehicle extending the company's surgical product portfolio into the soft-tissue surgical-robotics space.

---

FDA IDE pivotal trial pathway (cap-flag current submission posture)

Per DEPLOY's surgical cluster framework, Hugo operates the FDA IDE (Investigational Device Exemption) pivotal trial pathway for US market access. Per cap-flag-as-trust-signal, the current submission posture operates at cap-flag pending primary-source verification:

• IDE pivotal trial pathway: Medtronic operates an IDE-pathway US-approval strategy for Hugo, distinct from De Novo submission strategy (J&J Ottava) and direct 510(k) clearance with existing predicates.
• Current US submission state: cap-flagged; specific submission status (IDE-pivotal-active vs IDE-pivotal-data-submitted vs De Novo-pivoted vs subsequent 510(k) path) operates at lower verification posture pending primary-source confirmation.

Per DEPLOY's framework, the IDE-pivotal pathway framing is the load-bearing verified scope; specific current-submission-status verification requires primary-source confirmation per cap-flag-as-trust-signal discipline.

---

Commercial in CE-Mark regions (EU + select international markets)

Per DEPLOY's surgical cluster framework, Hugo is commercial in CE-Mark regions across the European Union + select international markets. Per cap-flag-as-trust-signal, the CE-Mark commercial deployment is the load-bearing verified scope:

• EU CE-Mark commercial: Hugo operates as a commercially-deployed surgical-robotic platform across EU member states under CE-Mark regulatory framework.
• Select international markets: additional non-US international deployment across markets that recognize CE-Mark or operate distinct regulatory frameworks accepting Hugo.

Per DEPLOY's framework, the non-US-market commercial deployment positions Hugo distinctively within the surgical cluster: distinct from Intuitive da Vinci's US-installed-base dominance + CMR Versius's international commercial deployment across EU + UK + Australia + India. The Medtronic + Hugo international commercial positioning operates as a Wave 1 cluster reference for the non-US-commercial-deployment scope.

---

Large-prime IDE-pivotal pathway archetype: Wave 1 triangle's third leg

Per DEPLOY's surgical cluster framework, Hugo's structural positioning anchors the Wave 1 surgical FDA-clearance triangle's third leg:

• Intuitive da Vinci: market-leader cleared-multi-procedure US-installed-base; 11,395 da Vinci + 1,041 Ion systems per SEC 10-Q.
• Medtronic Hugo: large-prime IDE-pivotal pathway; commercial in CE-Mark + international.
• Johnson & Johnson Ottava: De Novo submission January 2026; FDA records "not authorized to be marketed"; corporate-scale pre-market research-tier.

Per DEPLOY's framework, the Wave 1 triangle covers general-laparoscopy variance across FDA-clearance states at the large-prime tier: market-leader cleared + IDE-pivotal pathway + De Novo pre-market. Trade-press coverage framing the soft-tissue surgical-robotics market as "Intuitive + new entrants" without the IDE-pivotal-vs-De-Novo-vs-cleared distinction operates outside DEPLOY's primary-source-anchored verification of US-FDA-pathway variance.

---

Cap-flag: aggregator-quoted procedure-volume figures

Per cap-flag-as-trust-signal, aggregator-quoted procedure-volume figures for Hugo operate at lower verification posture pending Medtronic SEC-disclosed primary-source confirmation. Per DEPLOY's framework, the CE-Mark commercial deployment + IDE-pivotal pathway are the load-bearing verified scope; specific per-region procedure-volume or unit-installed figures cap-flagged pending primary-source confirmation.

---

Cohort positioning: large-prime IDE-pivotal pathway archetype

Per the surgical cluster framework, Medtronic Hugo anchors:

• Large-prime IDE-pivotal pathway archetype: US-FDA IDE pivotal trial pathway; distinct from De Novo + 510(k) pathways within the FDA-clearance-posture axis.
• Wave 1 surgical FDA-clearance triangle's third leg: Intuitive market-leader + Hugo IDE-pivotal + Ottava De Novo pre-market.
• Commercial in CE-Mark regions: EU + select international markets; non-US-commercial-deployment positioning.
• Medtronic NYSE: MDT large-prime parent: one of the largest medical-device companies globally; surgical-robotics extension via Hugo.

Contrast with cohort:

• Intuitive da Vinci: cleared multi-procedure; market-leader installed-base.
• Johnson & Johnson Ottava: De Novo submission January 2026; pre-market.
• CMR Versius: international commercial soft-tissue; UK-headquartered modular architecture.
• Moon Surgical Maestro: assistive-laparoscopy commercial-niche; FDA 510(k) K240598 cleared Jun 2024.
• Stryker Mako: large-footprint orthopedic; cross-tier (orthopedic vs Hugo soft-tissue).
• Smith+Nephew CORI: handheld imageless orthopedic; cross-tier.
• Zimmer Biomet ROSA: mid-size cross-domain (ortho + neurosurgery); cross-tier.

Consumer pricing surface for Medtronic Hugo is LIVE at deploy.report/price/medtronic-hugo per Agent B's existing /price coverage; registry institutional depth at Medtronic registry company + Hugo registry model.

For the canonical surgical cluster context, see the surgical robotics cluster. For the market-leader contrast, see what is Intuitive Surgical da Vinci. For the De Novo pre-market contrast, see what is Johnson & Johnson Ottava. For the canonical category umbrella, see what is physical AI. For methodology canonical references applicable to Medtronic Hugo: the 4-way autonomy-boundary taxonomy (replacement-robotics teleoperated tier; CE-Mark commercial + US IDE-pivotal pathway) + the 9-tier source-quality rubric (Medtronic SEC + FDA + reputable-press source classification).